TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02998060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screw Placement
Description: As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screw Placement
Description: As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
Study: NCT00653159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T380A intrauterine device (CuT380A)
Description: Teens are randomly assigned to Copper T380 after the screening visit
Study: NCT02998060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screw Placement
Description: As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)
Description: This robot will be used to guide pedicle screws into their trajectories.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D C-Arm (Ziehm Imaging, Nuremberg, Germany)
Description: This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
Study: NCT00881855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg Tablets (Sandoz, GmbH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
Study: NCT03370991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: 22 g/day freeze-dried blueberry powder for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 22 g/day placebo powder for 12 weeks
Study: NCT03625427

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoleic acid, 500 mg (Dose 1)
Description: Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoleic acid, 1,000 mg (Dose 2)
Description: Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
Study: NCT00426517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Horse Anti-human Thymocyte Globulin (h-ATG)
Description: Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus or equivalent based on response
Description: post Transplantation immunosuppressants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus or equivalent based on response
Description: post Transplantation immunosuppressants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus or equivalent based on response
Description: post Transplantation immunosuppressants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus or equivalent based on response
Description: post Transplantation immunosuppressants
Study: NCT00207259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki & Relaxation Response Therapy with Cognitive Restructuring
Description: Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki & Relaxation Response Therapy with Cognitive Restructuring
Description: Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant.
Study: NCT04872816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous airway positive pressure
Description: The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous airway positive pressure
Description: The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
Study: NCT03430817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicholine
Description: Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicholine
Description: Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
Study: NCT01317667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Study: NCT01444781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide
Description: 0.5 mL, Intramuscular each into the right and left deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide
Description: 0.5 mL, Intramuscular each into the right and left deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
Description: 0.5 mL (each), Intramuscular each into the right and left deltoid muscle
Study: NCT01599884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 1800 mg twice daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral acetylcysteine
Description: Identical placebo pills twice daily for 8 weeks
Study: NCT02254291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
Study: NCT02210078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Description: Given IV
Study: NCT02723734

Intervention type: OTHER
Intervention: Decipher® Testing
Description: Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.

Intervention type: OTHER
Intervention: Decipher® Testing
Description: Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
Study: NCT00698789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 5 mg of INCB019602 in AM with placebo administration in PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 20 mg in AM with placebo administration in PM
Study: NCT02104193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin in addition to radiation therapy
Description: simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
Study: NCT04038879

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of the heart
Study: NCT03772535

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomics Testing
Description: The doctor will use genetic test results to prescribe medications that are a most effective for subject.
Study: NCT02331758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
Study: NCT00691626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Insomnia plus Imagery Rehearsal
Description: patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Insomnia plus psychoeducation
Description: patients receive standard CBT for insomnia combined with psychoeducation
Study: NCT04348474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: All patients included in the study will receive AZT 500 mg per day for 5 days.
Study: NCT01291589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Treatment will include elements from effective interventions for reducing risky sexual behaviors
Study: NCT02167711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIRT Yttrium-90
Study: NCT03716648

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DISE-assisted titration
Description: Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSG-guided titration
Description: Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subjective titration
Description: Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
Study: NCT00698789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 5 mg in PM with placebo administration in AM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 20 mg in PM with placebo administration in AM
Study: NCT01617473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant with PBSCs
Description: mobilized PBSCs for 2 consecutive days
Study: NCT04078867

Intervention type: PROCEDURE
Intervention: tricuspid valve repair
Description: Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
Study: NCT04600440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
Study: NCT00253734

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (IM)
Description: 15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (IM)
Description: 15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (IM)
Description: 15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (IM)
Description: 15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
Study: NCT02986035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECA cream
Study: NCT02180698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR4 Agonist GLA-SE
Description: Given intratumorally
Study: NCT03661606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated Altitude Chamber
Description: Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study.
Study: NCT03609281

Intervention type: RADIATION
Intervention: Ultrasound assessement of uterine scar
Description: 3D ultrasound assessment of scar characteristics

Intervention type: RADIATION
Intervention: Ultrasound assessement of uterine scar
Description: 3D ultrasound assessment of scar characteristics
Study: NCT03163212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin/FOS
Description: Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin/FOS
Description: Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin/FOS
Description: Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
Study: NCT00928213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 40 units daily admission

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight Heparin
Description: 40-80 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Drug
Description: no treatment
Study: NCT03833648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UControl Pain App with Education
Description: The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
Study: NCT01116180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II receptor antagonists (Candesartan)
Description: Seven days of treatment with Candesartan 32 mg, capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule matching the active comparator. Given for 7 days once daily.
Study: NCT01121965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with ILM peeling
Description: Pars plana vitrectomy with ILM peeling
Study: NCT04566263

Intervention type: DEVICE
Group type: OTHER
Intervention: Neuroform EZ Stent System
Description: The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
Study: NCT02831816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZP Vehicle
Description: Apply topically.
Study: NCT02513667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiation
Description: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiation
Description: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
Study: NCT00697060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imexon + docetaxel
Description: Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
Study: NCT03529994

Intervention type: OTHER
Intervention: Enrollment
Description: All infants enrolled will have work of breathing assessed.